In a quiet lab at IMB-CNM-CSIC, a wafer-thin patch of graphene no larger than a sesame seed is already changing how we think about the brain. This isn’t science fiction—it’s a working neural interface that can both listen to and speak with brain cells, opening a two-way channel once thought too fragile to build. Developed by a team led by Prof. Jose A. Garrido and Dr. Anton Guimerà, the device marks a leap forward in treating neurological disorders, where timing, precision, and adaptability are everything. For conditions like epilepsy or Parkinson’s, current implants operate like megaphones in a library—blasting signals without hearing the whispers around them. But this new interface does both: it records ultra-low-frequency brain activity with unmatched sensitivity and delivers targeted electrical pulses—without interference. That means therapies could one day adapt in real time to a patient’s shifting brain state, rather than relying on fixed settings.
The breakthrough lies in the fusion of two graphene technologies into a single, flexible platform. On one side are monolayer graphene field-effect transistors (gFETs), capable of detecting neural signals down to 0.1 Hz—frequencies most implants miss entirely. On the other are microelectrodes made from nanoporous reduced graphene oxide (rGO), engineered to stimulate neurons with precision. Integrating both into one device was no small feat. Earlier attempts stumbled on artifacts—electrical echoes from stimulation that drowned out real brain signals. But this design keeps the channels clean. “The results showed that monitoring brain activity, including ultra-low frequency activity, is not affected by modulation,” says Dr. Guimerà. “For this reason, we can say that the device is able to listen and speak.”
Fabricated in the clean rooms of IMB-CNM-CSIC and ICN2, the interfaces were tested in live mouse models at University College London, where they successfully detected biomarkers and responded with tailored stimulation. This isn’t just lab-scale promise—the technology is already moving toward people. INBRAIN Neuroelectronics, a spin-off founded in 2019 by the same research ecosystem, has licensed the core graphene technologies and completed its first human trial, proving initial safety and efficacy in clinical settings. The company’s goal? To bring adaptive, graphene-powered neural therapies to patients within the decade.
This milestone stands on years of collaboration. A 2018 Nature Materials study first demonstrated graphene’s ability to capture ultra-low brain signals; a 2023 follow-up in Nature Nanotechnology advanced the nanoporous electrode design. Now, with bidirectional communication proven, the path is clear: smarter implants that don’t just intervene, but understand. As neuroscience inches toward personalized brain medicine, this flexible patch of carbon may be one of the first whispers of a much larger conversation.